Endonovo Therapeutics (OTCQB: ENDV), a commercial-stage developer of noninvasive Electroceutical(R) therapeutic devices, on Tuesday announced its financial results for the quarter ended September 30, 2019. Among the highlights, Endonovo reported a 153% increase in revenues for the three months ended September 30, 2019 to $54,039 and a 293% increase in revenues for the nine months ended September 30, 2019 to $161,720, as compared to the same periods last year. “Although our third-quarter operating results and our revenues failed to meet previously announced projections, the efforts throughout the quarter and first nine-months of this year have been extremely positive considering the amount of hospitals we are currently in and the number of hospitals evaluating SofPulse(R) to date,” Endonovo Therapeutics CEO Alan Collier said in the news release. “The national rollout has been successful, however, hospitals testing and evaluation periods have been longer than initially expected. We respect the process, the policies and procedures some hospitals have before accepting a product into their medical facility and as part of their post-operative pain management protocols. As such, we continue to expand our client base and have seen significant traction in building Endonovo into a premier supplier to hospitals nationwide for post-operative pain.”
To view the full press release, visit http://nnw.fm/YyxB8
About Endonovo Therapeutics
Endonovo Therapeutics is a commercial-stage developer of noninvasive, wearable Electroceuticals(R) therapeutic devices. The company’s current portfolio of commercial and clinical-stage wearable Electroceuticals(R) therapeutic devices addresses wound healing, pain, postsurgical pain and edema, cardiovascular disease, chronic kidney disease, and central nervous system (“CNS”) disorders including traumatic brain injury (“TBI”), acute concussions, post-concussion syndrome and multiple sclerosis. The company’s noninvasive Electroceutical(R) therapeutic device, SofPulse(R), which uses pulsed short-wave radiofrequency at 27.12 MHz, has been FDA cleared and CE marked for the palliative treatment of soft-tissue injuries and postoperative pain and edema and has CMS national coverage for the treatment of chronic wounds. The company’s current portfolio of preclinical-stage Electroceuticals(R) therapeutic devices addresses chronic kidney disease, liver-disease nonalcoholic steatohepatitis (NASH), cardiovascular and peripheral artery disease (PAD), and ischemic stroke. The company’s noninvasive, wearable Electroceuticals(R) therapeutic devices work by restoring key electrochemical processes that initiate anti-inflammatory and growth-factor cascades necessary for healing to occur. For more information, visit the company’s website at www.Endonovo.com.
NOTE TO INVESTORS: The latest news and updates relating to ENDV are available in the company’s newsroom at http://nnw.fm/ENDV
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.